leisure time -WSS

leisure time

author：focus 2025-09-27 23:01:22 - browse：26124

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： What's changing in Medicare's open enrollment this year?

WSS

Massive project maps cells in human brain in unprecedented detail

Massive project maps cells in human brain in unprecedented detail

There’s no way to know how good AI health technologies are

Life sciences deals on track to hit lowest point since 2017

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Medicare reduced heart disease by changing how it pays doctors

hotspot

leisure time

leisure time

Jerome Adams on the need for new antivirals for Covid

STAT Readout Newsletter: Today in biotech, life science news

ChatGPT in medicine: STAT answers readers' burning questions

Hospital price transparency does save money, advocate argues

Supreme Court strikes down use of affirmative action

Life sciences deals on track to hit lowest point since 2017

Duchenne breakthrough therapy leaves behind pioneering families

Eli Lilly expects to double planned employment in Boston center

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Why health workers in Gaza are injured or die at high rates

hotspot

Hospital price transparency does save money, advocate argues

How climate

STAT Summit: GSK CEO on pharma giant's new direction

NIH confirmation hearing shows politicization of research

What the Wegovy shortage looks like for doctors — and for patients

Readout LOUD podcast: Merger Mondays, Ozempic panic

focus

explore

leisure time

focus